The introduction about Levodopa and the demonstration that dopamine loss is the key pathological feature of PD have revolutionized the field of PD therapeutics. In most cases of Parkinson’s disease, protein deposits called Lewy Bodies. It is unclear whether Lewy bodies play an important role in killing nerve cells or just part of the cells which are responsible to the Parkinson’s disease. Nearly 15 percent of people with PD have motor symptoms that are not controlled with levodopa. A group of drugs that act directly on dopaminergic reports called dopamine against is used as adjuncts to levodopa in the treatment of PD.
Related: Parkinson’s Conference | Parkinson’s Disease Conference | Parkinson’s Congress | Movement Disorder Conferences | Neuroscience Conferences | Neurology Conferences
Related Conferences:
World Congress on Parkinson’s and Movement Disorders, July 23-24, 2019 at Berlin, Germany | 5th Global Experts Meeting on Parkinson’s, Huntington’s & Movement Disorders, May 08-09, 2019, at Tokyo, Japan | 5th World Parkinson Congress, June 4-7,2019, at Kyoto, Japan | 5th International Conference on Parkinson’s disease and Movement Disorders, October 19-20, 2018, at New York, USA | Movement Disorders in Children and Young Adults, November 22-23, 2018, at Groningen, Netherlands
Related Association and Societies:
American Academy of Neurology; Movement Disorders Society; The International Parkinson and Movement Disorder Society; Canadian Movement Disorders Group; UK Parkinson’s Action Network; European Neurological Society; European Parkinson’s Disease Association; Danish Movement Disorder Society; Italian Society for the study of Parkinson Disease; Extrapyramidal Diseases and Dementia; Movement Disorder Society of Australia; Parkinson’s Disease and Movement Disorders Society of India; Australian Parkinson’s Disease Society; Movement Disorder Society of Japan
All accepted abstracts will be published in respective Allied Academies Journals.
Abstracts will be provided with Digital Object Identifier by
